Research progress on prognosis and influencing factors of patients with radioactive iodine-refractory differentiated thyroid cancer
The incidence of thyroid cancer is steadily rising,with differentiated thyroid cancer(DTC)accounting for most cases.While stand-ard treatment offers a good prognosis for most DTC patients,a small subset experiences resistance to radioactive iodine during 131I therapy.This resistance is characterized by a lack of iodine uptake in lesions or continued disease progression,defined as radioactive iodine-refract-ory differentiated thyroid cancer(RAIR-DTC).Patients with RAIR-DTC face a significantly poorer prognosis and increased mortality.Several factors influence the prognosis of patients with RAIR-DTC,including age,tumor characteristics,genetic alterations,serum biomarkers,ima-ging findings,and different treatment modalities.This article provides a comprehensive overview of the outcomes and prognostic factors as-sociated with RAIR-DTC,aiming to provide assistance in timely evaluating the survival expectations of RAIR-DTC patients and guiding clinical decision-making.
NETL
NSTL
万方数据
